Glenmark set for US 'upside' amid EMs volatility
This article was originally published in Scrip
Executive Summary
Shares of Glenmark Pharmaceuticals spurted on Indian bourses following the firm's good showing in the first quarter of FY16 and expectations of a potential undefined "upside" in the US in the coming quarters.